MIAMI--(BUSINESS WIRE)--June 3, 2005--EDot.com, Inc. (Pink Sheets:ECMM - News) announced the execution of a definitive term sheet to acquire 100% of the common stock of NanoViricide, Inc., a company engaged in the development of targeted nanomedicines that act like molecular Trojan horses to combat various viral infections, including HIV, HCV, Herpes, Asian (bird) Flu and Influenza. "I've been on the front lines dealing with HIV for almost 25 years," stated Eugene Seymour, M.D., the CEO of NanoViricide, Inc. and of EDot.com, Inc., "at the bedside as a physician, in the lab as a researcher, and in various countries collecting data. This disease has had a profound effect on my life, and I have been looking for something like this for the last 25 years. I feel that this technology will position us to become a world leader in the treatment of HIV-infected people."
"This technology is ahead of the market. It is a disruptive technology in the therapy of viral diseases," noted Anil Diwan, Ph.D., President of NanoViricide Inc., and the research scientist who invented the NanoViricide(TM) particle system. He continued, "Our NanoViricide(TM) drug is designed like a chemical missile. It has a number of recognition 'ligands' on its surface, that are specific to a single type of virus. They are like the GPS system on a directed missile. They will identify the enemy and attach to specific 'landing sites' on the enemy target. The NanoViricide(TM) drug, after landing, spreads itself all over the virus particle, and thus completely neutralizes and disables the virus particle from binding to its target, a human cell." Dr. Diwan added, "Dr. Seymour knows most of the significant players in the HIV research and charitable communities. His devotion to finding answers to this most difficult epidemic leads us to feel confident that we are working in the right direction."
NanoViricide, Inc.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
i hope so tex, just got home from work I was bored and checked news, i don't always bother with news. so far so good. was .75 at one point.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
yeah, I'm gonna delve into this real hard--I like the sound of "disruptive technology." I think the pdf said main office is somewhere in texas, but I didn't recognize the name.
quote:Originally posted by cruz: what's the deal. i couldn't get filled.
i sat for about 15 minutes over the bid swearing then i got filled. I was double checking any level 2 I could find while dialing the broker.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
ECMM numbers from the TA >> 300MM Auth 79MM OS 9.6MM Float Empire Stock Transfer Inc. 7251 West Lake Mead Boulevard, Suite 300 Las Vegas, NV 89128-8351
Article for Edot Com Com Inc (OTHER OTC:ECMM) 2:44 PM most recent headlines
SPONSORED LINKS Get listed here
Jim Cramer’s Every Investment and Trade - Find out what Cramer is buying for his $3MM portfolio. Special Offer ...
Start Currency Trading Today - Risk Free - 24-hour commission-free trading, 100-to-1 leverage of your capital, free ...
Ready to Try Currency Trading? - Get started with a risk-free virtual trading account from FOREX.com. Advanced tradi...
eSignal - Know More, Make More - Stay on top of the latest stock market trends with eSignal. Providing award-winnin...
EDot.com, Inc. Announces Term Sheet to Acquire NanoViricide, Inc. FRIDAY, JUNE 03, 2005 2:44 PM - BusinessWire
ECMM 0.29 +0.07
Enter Symbol:
Enter Keyword:
MIAMI, Jun 03, 2005 (BUSINESS WIRE) -- EDot.com, Inc. (Pink Sheets:ECMM) announced the execution of a definitive term sheet to acquire 100% of the common stock of NanoViricide, Inc., a company engaged in the development of targeted nanomedicines that act like molecular Trojan horses to combat various viral infections, including HIV, HCV, Herpes, Asian (bird) Flu and Influenza.
"I've been on the front lines dealing with HIV for almost 25 years," stated Eugene Seymour, M.D., the CEO of NanoViricide, Inc. and of EDot.com, Inc., "at the bedside as a physician, in the lab as a researcher, and in various countries collecting data. This disease has had a profound effect on my life, and I have been looking for something like this for the last 25 years. I feel that this technology will position us to become a world leader in the treatment of HIV-infected people."
"This technology is ahead of the market. It is a disruptive technology in the therapy of viral diseases," noted Anil Diwan, Ph.D., President of NanoViricide Inc., and the research scientist who invented the NanoViricide(TM) particle system. He continued, "Our NanoViricide(TM) drug is designed like a chemical missile. It has a number of recognition 'ligands' on its surface, that are specific to a single type of virus. They are like the GPS system on a directed missile. They will identify the enemy and attach to specific 'landing sites' on the enemy target. The NanoViricide(TM) drug, after landing, spreads itself all over the virus particle, and thus completely neutralizes and disables the virus particle from binding to its target, a human cell." Dr. Diwan added, "Dr. Seymour knows most of the significant players in the HIV research and charitable communities. His devotion to finding answers to this most difficult epidemic leads us to feel confident that we are working in the right direction."
NanoViricide, Inc.
NanoViricide, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricide, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types, HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that in 2006, it will license the products to major pharmaceutical companies.
Forward-Looking Statements
Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or reports and filings with the Securities and Exchange Commission, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.
SOURCE: EDot.com, Inc.
For EDot.com, Inc., Miami Robert Weidenbaum, 305-860-3307
Copyright Business Wire 2005
-------------------- Do dd before you buy any stocks I post on Posts: 22 | From: Midwest | Registered: May 2005
| IP: Logged |
this has float and os from 2005 its a pinkie, tough diggin so far.
this has some interesting company info. looking for info on the aquired company....
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
here's a mention of "Dr. Seymour," of nanoviricide--all I've found so far...to be fair to him, tho, have'nt been able to spend much time, yet...
posted
Biography: Anil Diwan, Ph.D. received a Bachelors degree from Indian Institute of Technology, Bombay, India (1980), and a Ph.D. in Biochemical Engineering from Rice University, Houston, TX (1986), both premier institutions. He has published scientific papers in a wide range of fields, and has a patent application in polymer chemistry. His first software project was the simulation of a Distillation Column in Petrochemical Industry using FORTRAN 77. He has used various computer languages, mostly for solving scientific and numerical problems, and has taught FORTRAN, APL, and Java. In his own company, since 1992, he has been managing a number of different types of projects, some with software aspects. He began consulting in Information Technology in 1998. He has worked at companies such as Cendant, At-Plan (now taken over by nielsenratings.com), Sprint, Aetna, and Bristol-Myers Squibb in all aspects of software development. He has worked as a Team Leader, with responsibilities for requirements elicitation and management, business analysis and modeling, application definition, J2EE and non-J2EE design with patterns, implementation algorithms, database modeling, business rules -- through testing and deployment. With his extensive experience in business software development, he has been thinking about the process a software project undergoes. He will be thinking aloud with us, in order to develop some principles of what he calls “Managed Evolutionary Programming.”
although it wasn't Dorothy then it was David: they were the sole owners of Amazon: David Mortenson 2,250,000 90% P. O. Box 5034 Alvin TX 77512-5034 ---------------------------------------- ---------- ---------- J. P. Beehner 250,000 10% P. O. Box 5034 Alvin TX 77512-5034
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
teaches here: Audio with graphics and transcript "HIV Case Study" Eugene Seymour, M.D., M.P.H. Medical Director Center for AIDS Research and Training, Inc. http://www.medschool.com/futuretense_cs/ MedSchool/DistanceLearning/distancetest/Jay/new/ HIVlite/lecture/scrub/frameset.htm
anyone with new england journal of medicine subscription: content.nejm.org/cgi/content/full/328/23/1717
quote:Originally posted by BuyTex: here's a mention of "Dr. Seymour," of nanoviricide--all I've found so far...to be fair to him, tho, have'nt been able to spend much time, yet...